| OBJECTIVE: The purpose of this study was to observe the pharmacokinetics of genetic recombinative human basic fibroblast growth factor (rhbFGF) after intravenous injection of rhbFGF and to confirm whether rhbFGF can penetrate the blood-cochlea barrier or the blood-cerebrospinal fluid barrier and the blood-brain barrier.METHOD: The rhbFGF contents in serum, cerebrospinal fluid (CSF), and brain of adult guinea pigs were measured by a indirect ELISA method at 3 min, 5min, 10min, 20min, 30min, 1hr and 1.5hr after intravenous injection of 3ug/100g rhbFGF. The contents of rhbFGF in serum and cochlear external lymph fluid (CELF) were assayed with the same method at 3min, 5min, lOmin and 20min after intravenous injection of double-dosage rhbFGF.RESULT: The half-life time period of rhbFGF in serum was 7.456min. The rhbFGF concentration in serum decreased fast in 20min after intravenous injection, but it had a gradual decline later and could not be found at 1.5hr after intravenous injection. rhbFGF was found in CSF and brain in less than 20min after injection. Compared with the content of rhbFGF in blood, rhbFGF content in CSF and brain was 56.1-76.4% and 51.4-67.7% of it in blood respectively. The rhbFGF contents had not statistically significant differences between the same time groups of CSF and brain (P>0.05). rhbFGF was found in CELF at 3min, 5min and lOmin after double-dosage injection, the content of it was 15.7-22.4% of its concentration in blood at the same time.CONCLUSION: rhbFGF had a short half life time in blood, italso had a better capability of penetration through the blood-brain barrier and blood-cerebrospinal barrier so that it could cross rather freely between the brain and CSF. Furthermore, rhbFGF could penetrate the blood-cochlea barrier, but had a low content and a short existence in cochlear external lymph fluid. |
PDF Full Text Request